Key Metrics 
Check Before You Invest 
10 Yrs X-Ray 
Valuation 
Analyst Note 
Qtr. Results 
Financials 
News 
About
NGL Fine-Chem Ltd (NGLFINE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524774 NSE: NGLFINE Pharmaceuticals & Drugs | Small Cap | NGL Fine-Chem Share Price
₹3,265.80 -14.80 (-0.45%)
As on 04-Aug'26 12:17
NGL Fine-Chem Ltd (NGLFINE)
Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 524774 NSE: NGLFINE Pharmaceuticals & Drugs | Small Cap | NGL Fine-Chem Share Price
₹3,265.80 -14.80 (-0.45%)
As on 04-Aug'26 12:17
Key Metrics
Valuation Multiples
Market Cap
₹2,027 Cr.
Current Price
₹3,265.8
52-Week Low / High
₹1,180 / 3,435
TTM EPS
₹67.4
TTM Sales
₹489 Cr.
Book Value per Share
₹517.9
P/E Ratio
48.68
Higher than its 5-year historical median
Industry PE
54.3
Price to Book (P/B)
6.33
Higher than its 5-year historical median
Price to Sales (P/S)
4.15
Higher than its 5-year historical median
EV/EBITDA
28.25
Higher than its 5-year historical median
Dividend Yield
0.05%
Profitability Efficiency
Return on Equity (ROE)
13.89%
Outperforms industry median
Return on Capital Employed (ROCE)
14.96%
Outperforms industry median
Return on Assets (ROA)
8.55%
Operating Profit Margin
13.9%
Net Profit Margin
8.52%
Gross Profit Margin
14.5%
Growth Momentum
1-yr vs 3-yr growth
1-yr vs 3-yr growth
Sales Growth (1 Year)
Improving versus 3-year growth rate
36.04%
Operating Profit Growth (1 Year)
Improving versus 3-year growth rate
129.92%
Net Profit Growth (1 Year)
Improving versus 3-year growth rate
129.62%
Asset Quality
Promoter Holding
72.49%
Pledged shares (%) of Promoter's holding (%)
0.00%
Reserves
₹317 Cr.
Equity
₹3.1 Cr.
Face Value
₹5
All Time Low / High
₹0.40 / 3789.45
Check Before You Invest
Quality
Somewhat GoodValuation
Somewhat OvervaluedCheck Valuation charts
Price Trend
Strong
Is NGL Fine-Chem Ltd a good quality company?
NGL Fine-Chem Ltd is a average quality company, based on a somewhat consistent multi-year financial track record.
This assessment is based on company’s performance on Revenue growth, ROCE, Equity and Assets, key margin ratios, cash conversion cycle, and debt to cash flow from operations and how it compares with its long term averages.
We have analysed the performance of the company on the following:
-
How has it performed on generating Profits?
By checking its Revenue growth, Gross, Operating and Net Margins compared to its last 5-year median.
-
How efficiently has it utilized Capital?
By checking its ROCE, ROA, ROE and its Cash Conversion Cycle.
-
How is it managing its Debt?
By checking its Debt to Equity and Cash Flow from Operations.
How does NGL Fine-Chem Ltd performance compare with that of its Peers?
Revenue growth of NGL Fine-Chem Ltd vs industry peers?
NGL Fine-Chem Ltd revenue CAGR is 13.62%, compared to the industry median CAGR of 5.55%, indicating faster growth and gaining its market share.
Promoter shareholding and pledge status of NGL Fine-Chem Ltd?
Promoters hold 72.49% of the NGL Fine-Chem Ltd, with 0.00% of their stake pledged, indicating no pledge risk.
Stock return of NGL Fine-Chem Ltd over the last decade?
Over the last 9 year(s), the stock has delivered a CAGR of 29% based on the current price.
10 Year X-Ray :
Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year endData adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
What is a Financial Track Record? How to read this chart in order to understand the data present here?
Financial track record gives insight into the company's performance on key parameters over the past ten years. MoneyWorks4me’s proprietary colour codes make it easy for retail investors to gauge the company’s past performance.
NGL Fine-Chem Ltd has performed well in some of the past ten years indicating its past ten year financial track record is somewhat good
Value Creation ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % ⓘ | 33.8% | 21.7% | 27.6% | 13.7% | 51.9% | 34.7% | 11.5% | 18.9% | 8.3% | 15% | - |
| Value Creation Index ⓘ | 1.4 | 0.6 | 1.0 | 0.0 | 2.7 | 1.5 | -0.2 | 0.4 | -0.4 | 0.1 | - |
Growth Parameters ⓘ |
|||||||||||
| Sales ⓘ | 99.7 | 114 | 153 | 152 | 258 | 319 | 275 | 329 | 359 | 489 | 489 |
| Sales YoY Gr. | - | 14% | 34.8% | -0.7% | 69.7% | 23.4% | -13.7% | 19.6% | 9.2% | 36% | - |
| Adj EPS ⓘ | 22.9 | 18.6 | 29 | 16.6 | 88.1 | 84.6 | 29.4 | 58.4 | 26.4 | 65.9 | 67.4 |
| YoY Gr. | - | -18.9% | 56% | -42.7% | 430% | -4% | -65.2% | 98.4% | -54.8% | 149.3% | - |
| BVPS (₹) ⓘ | 96.2 | 116.6 | 149.1 | 163.8 | 251.6 | 334.4 | 365 | 425.4 | 452.6 | 517.9 | 517.9 |
| Adj Net Profit ⓘ | 14.2 | 11.5 | 17.9 | 10.3 | 54.5 | 52.3 | 18.2 | 36.1 | 16.3 | 40.7 | 42 |
| Cash Flow from Ops. ⓘ | 9.9 | 22.4 | 8.9 | 19.6 | 26.6 | 15.8 | 31.9 | 11.1 | 22 | 34.7 | - |
| Debt/CF from Ops. ⓘ | 2.3 | 1.2 | 3.1 | 1.4 | 0.6 | 1.9 | 1 | 3.1 | 3.5 | 3.5 | - |
CAGR ⓘ
| 9 Years | 5 Years | 3 Years | 1 Years | |||||
|---|---|---|---|---|---|---|---|---|
| Sales ⓘ | 19.3% | 13.6% | 21.1% | 36% | ||||
| Adj EPS ⓘ | 12.4% | -5.7% | 30.8% | 149.3% | ||||
| BVPSⓘ | 20.6% | 15.5% | 12.4% | 14.4% | ||||
| Share Price | 28.9% | -2.9% | 17.6% | 154.2% | ||||
Key Financial Parameters ⓘ
| Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity % ⓘ | 27.3 | 17.5 | 21.8 | 10.6 | 42.4 | 28.9 | 8.4 | 14.8 | 6 | 13.6 | 13 |
| Op. Profit Mgn % ⓘ | 25.6 | 19 | 21.1 | 15.2 | 29.8 | 20.7 | 10.4 | 13.6 | 7.5 | 13.9 | 12.1 |
| Net Profit Mgn % ⓘ | 14.2 | 10.1 | 11.7 | 6.8 | 21.1 | 16.4 | 6.6 | 11 | 4.5 | 8.3 | 8.5 |
| Debt to Equity ⓘ | 0.4 | 0.4 | 0.3 | 0.3 | 0.1 | 0.2 | 0.1 | 0.1 | 0.3 | 0.4 | 0.2 |
| Working Cap Days ⓘ | 187 | 198 | 167 | 184 | 132 | 166 | 216 | 186 | 194 | 169 | 91 |
| Cash Conv. Cycle ⓘ | 81 | 65 | 55 | 79 | 49 | 74 | 99 | 76 | 76 | 74 | 43 |
Valuation of NGL Fine-Chem - Standalone
Analyst's Notes
No data found!
Management X-Ray
Shareholding Pattern
Promoter's Holding & Share Pledging
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
* Pledged shares as % of Promoter's holding (%)
Financials
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 100 | 114 | 153 | 152 | 258 | 319 | 275 | 329 | 359 | 489 |
| Operating Expenses ⓘ + | 74 | 92 | 121 | 131 | 181 | 253 | 246 | 284 | 333 | 428 |
| Operating Profit ⓘ | 25 | 22 | 32 | 21 | 77 | 66 | 29 | 45 | 27 | 61 |
| Operating Profit Margin (%) | 25.5% | 19.0% | 21.1% | 13.7% | 29.8% | 20.7% | 10.4% | 13.6% | 7.4% | 12.5% |
| Other Income ⓘ + | 1 | 3 | 4 | 3 | 9 | 13 | 8 | 16 | 10 | 15 |
| Interest ⓘ | 1 | 2 | 3 | 3 | 2 | 2 | 2 | 2 | 3 | 5 |
| Depreciation ⓘ | 3 | 5 | 6 | 7 | 7 | 8 | 8 | 8 | 9 | 16 |
| Profit Before Tax ⓘ | 23 | 18 | 28 | 14 | 76 | 69 | 27 | 51 | 24 | 55 |
| Tax ⓘ | 8 | 5 | 7 | 4 | 21 | 17 | 6 | 12 | 6 | 13 |
| Profit After Tax | 15 | 13 | 20 | 11 | 55 | 52 | 20 | 39 | 18 | 42 |
| PAT Margin (%) | 14.9% | 11.1% | 13.1% | 7.0% | 21.5% | 16.4% | 7.3% | 11.7% | 5.1% | 8.5% |
| Adjusted EPS (₹) | 24.1 | 20.5 | 32.6 | 17.2 | 89.8 | 84.6 | 32.6 | 62.4 | 29.4 | 67.4 |
| Dividend Payout Ratio (%) | 0% | 0% | 5.40% | 10.20% | 2% | 2.10% | 5.40% | 2.80% | 6% | 2.60% |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Equity and Liabilities | |||||||||||
| Shareholders Fund + | 59 | 72 | 92 | 101 | 155 | 207 | 226 | 263 | 280 | 320 | |
| Debt + | 20 | 24 | 23 | 23 | 11 | 27 | 30 | 32 | 72 | 108 | |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Trade Payables | 14 | 24 | 16 | 21 | 27 | 35 | 23 | 47 | 48 | 60 | |
| Others Liabilities ⓘ | 17 | 14 | 18 | 11 | 12 | 10 | 9 | 11 | 32 | 55 | |
| Total Liabilities ⓘ | 111 | 133 | 149 | 156 | 206 | 278 | 288 | 353 | 432 | 542 | |
Fixed Assets | |||||||||||
| Net Fixed Assets ⓘ + | 25 | 56 | 61 | 61 | 58 | 59 | 59 | 60 | 120 | 144 | |
| CWIP ⓘ | 16 | 3 | 0 | 0 | 1 | 6 | 26 | 46 | 50 | 95 | |
| Investments ⓘ | 6 | 6 | 9 | 14 | 33 | 32 | 43 | 57 | 63 | 43 | |
| Inventories | 12 | 17 | 19 | 28 | 38 | 55 | 27 | 43 | 49 | 68 | |
| Trade Receivables | 30 | 28 | 33 | 26 | 38 | 65 | 65 | 83 | 80 | 125 | |
| Cash Equivalents | 2 | 4 | 3 | 3 | 5 | 1 | 13 | 2 | 5 | 3 | |
| Others Assets ⓘ | 20 | 19 | 25 | 23 | 34 | 60 | 54 | 63 | 65 | 65 | |
| Total Assets ⓘ | 111 | 133 | 149 | 156 | 206 | 278 | 288 | 353 | 432 | 542 | |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow From Operating Activity ⓘ + | 10 | 22 | 9 | 20 | 27 | 16 | 32 | 11 | 22 | 35 |
| Cash Flow From Investing Activity ⓘ + | -10 | -21 | -10 | -19 | -24 | -16 | -24 | -17 | -58 | -65 |
| Cash Flow From Financing Activity ⓘ + | 0 | 0 | 0 | -1 | -1 | -1 | -1 | -1 | 36 | 30 |
| Net Cash Flow ⓘ | -0 | 1 | -1 | -0 | 2 | -1 | 7 | -7 | 0 | 0 |
| PARTICULARS | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | Mar'24 | Mar'25 | Mar'26 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ratios | ||||||||||
| ROE (%) | 28.73 | 19.22 | 24.52 | 10.97 | 43.22 | 28.86 | 9.31 | 15.78 | 6.69 | 13.89 |
| ROCE (%) | 33.8 | 21.68 | 27.63 | 13.65 | 51.9 | 34.71 | 11.5 | 18.93 | 8.29 | 14.96 |
| Asset Turnover Ratio | 1.13 | 0.95 | 1.08 | 1 | 1.43 | 1.32 | 0.97 | 1.03 | 0.92 | 1 |
| PAT to CFO Conversion(x) | 0.67 | 1.69 | 0.45 | 1.82 | 0.49 | 0.31 | 1.6 | 0.28 | 1.22 | 0.83 |
| Working Capital Days | ||||||||||
| Receivable Days | 107.30 | 91.20 | 72.40 | 71.10 | 45.10 | 58.70 | 86.30 | 82.30 | 82.80 | 76.60 |
| Inventory Days | 37.40 | 45.20 | 42.20 | 55.80 | 46.50 | 53.30 | 54.50 | 38.60 | 46.60 | 43.60 |
| Payable Days | 123.20 | 145.30 | 110.70 | 97.40 | 73.50 | 65.50 | 70.50 | 82.90 | 94.10 | 81.60 |
Top 5 Mutual Funds Holding
Last Visited Stocks
Announcements
NGL Fine-Chem Ltd FAQs
The current trading price of NGL Fine-Chem on 04-Aug-2026 12:17 is ₹3,265.8.
Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 03-Aug-2026 the market cap of NGL Fine-Chem stood at ₹2,026.8 Cr
The latest P/E ratio of NGL Fine-Chem as of 03-Aug-2026 is 48.68.
The latest P/B ratio of NGL Fine-Chem as of 03-Aug-2026 is 6.33.
The 52-week high of NGL Fine-Chem is ₹3,435.3 and the 52-week low is ₹1,180.
The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of NGL Fine-Chem is ₹489 ( Cr.) .
Past 10 year's financial track record analysis by Moneyworks4me indicates that NGL Fine-Chem Ltd is a average quality company.
The key valuation ratios of NGL Fine-Chem Ltd's currently when compared to its past seem to suggest it is in the Somewhat overvalued zone.
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of NGL Fine-Chem Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
About NGL Fine-Chem Ltd
NGL Fine-chem is a manufacturer of pharmaceuticals and intermediates for usage in veterinary and human health. It caters to various global companies to custom manufacture high quality pharmaceuticals with reliability and flexibility.
Its business is modelled around the changing customer demands and their ability to offer value-added innovative solutions to meet and even exceed these demands.
Utilizing its expertise in complex multi-stage organic synthesis, it continues to expand the product portfolio with new products.
It has established a strong presence in global pharmaceutical companies with its commitment to competitive prices, delivery schedules, international quality standards and constant technological upgradation.
NGL Fine-chem Ltd has a strong focus on developing intellectual property as a key differentiator and as a platform for further growth up the pharma value chain. It respect intellectual property and invest in developing it as a key growth driver for the future.
Product range of the company includes:
Pharmaceutical like Diminazene Aceturate, Diminazene Diaceturate, Homidium Chloride, Nitroxynil, Clorsulon, Homidium Bromide, Parvaquone, Carprofen, Buparvaquone and Isometamidium Chloride Hydrochloride for:
- Animal health
- Human health
- Intermediate- 4 Aminobenzamidine Dihydrochloride, 3 Aminobenzamidine Dihydrochloride, Ezetimibe Intermediates etc
- Finished dosages form- Homidium Chloride Tablets, Diminazene Aceturate Granules
Achievements/ recognition
An ISO 9001:2000 accredited company
You have 4 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now
